Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for...

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Follicular lymphoma is a heterogeneous cancer with variable patient outcomes.
• The prognostic value of somatic mutations in follicular lymphoma has not been fully assessed.
• Improved risk stratification is needed for patients receiving first-line immunochemotherapy.

Purpose of the Study:

• To develop and validate a prognostic model integrating gene mutations and clinical factors for follicular lymphoma.
• To enhance risk stratification for patients undergoing first-line immunochemotherapy.
• To identify patients at highest risk of treatment failure.

Main Methods:

• Retrospective DNA deep sequencing of 74 genes in 151 follicular lymphoma biopsy specimens.
• Development of a clinicogenetic risk model (m7-FLIPI) incorporating gene mutations (EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP, CARD11), FLIPI, and ECOG performance status.
• Validation of the m7-FLIPI model in an independent cohort of 107 patients.

Main Results:

• The m7-FLIPI model identified a high-risk group with significantly poorer 5-year failure-free survival (38.29%) compared to the low-risk group (77.21%) in the training cohort.
• In the validation cohort, m7-FLIPI also distinguished high-risk (25.00% 5-year FFS) from low-risk (68.24%) patients.
• The m7-FLIPI model demonstrated superior performance over mutation-only models and FLIPI alone in predicting failure-free survival.

Conclusions:

• Integrating somatic mutation status with clinical factors significantly improves prognostication for follicular lymphoma patients.
• The m7-FLIPI model is a promising tool for identifying patients at high risk of treatment failure.
• This clinicogenetic approach supports personalized treatment strategies in follicular lymphoma.